Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817-Reference-Cited by-同舟云学术

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

Published:2023-01 Issue:1 Volume:18 Page:79-92
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Paz-Ares Luis G.,Ciuleanu Tudor-Eliade,Pluzanski Adam,Lee Jong-Seok,Gainor Justin F.,Otterson Gregory A.,Audigier-Valette Clarisse,Ready Neal,Schenker Michael,Linardou Helena,Caro Reyes Bernabe,Provencio Mariano,Zurawski Bogdan,Lee Ki Hyeong,Kim Sang-We,Caserta Claudia,Ramalingam Suresh S.,Spigel David R.,Brahmer Julie R.,Reck Martin,O’Byrne Kenneth J.,Girard Nicolas,Popat Sanjay,Peters Solange,Memaj Arteid,Nathan Faith,Aanur Nivedita,Borghaei Hossein

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline update summary;Hanna;JCO Oncol Pract,2020

2. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;N Engl J Med,2019

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-instructed CD14⁺CD4⁺T cells within the tumor microenvironment are associated with TNF⍺ signaling and prolonged survival in non-small cell lung cancer;2024-08-06

2. Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018–2022;Journal for ImmunoTherapy of Cancer;2024-08

3. Updates on the Management of Colorectal Cancer in Older Adults;Cancers;2024-05-10

4. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice;Experimental Hematology & Oncology;2024-03-01

5. First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non–Small-Cell Lung Cancer: Are We Ready to Use It?;Journal of Clinical Oncology;2024-02-01